The Latest Breaking News from Bluebird

The latest Bluebirds news from Cardiff City Stadium

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

The latest Bluebirds transfer news from Cardiff City Stadium

The Bluebirds' work in this transfer window has been swift and much-needed, but more must be done before the season kicks off in earnest

The Bluebirds have confirmed the appointment of new coaches on Wednesday morning and one will certainly have his work cut out for him in the coming weeks

The U.S.

The FDA signaled in briefing documents released that it may approve Bluebird bio Inc's (NASDAQ:BLUE) beti-cel gene therapy to treat β-thalassemia for those who require regular blood transfusions. The Prescription Drug User Fee Act (PDUFA) goal dates for beti-cel and eli-cel are August 19 and September 16. Bluebird bio's blood disorder treatment demonstrates "clinically meaningful"…

The latest Bluebirds transfer news from Cardiff City Stadium

Bluebird Bio Inc (NASDAQ:BLUE) is laying off about 30% of its workforce before the FDA decides the fate of two of its gene therapies. The gene therapy-focused company is showing the exit to nearly one-third of its staff to extend its cash runway into the first half of 2023 and save $160 million…